Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Immune checkpoint inhibitors (ICPis) have revolutionized cancer therapy with broad activities against a wide range Set of malignancies.However, in many malignancies their efficacy remains limited due to the primary resistance.Furthermore, a high percentage of patients develop progression due to the secondary resistance even after obtaining a Body S